ACADIA Pharmaceuticals
OverviewSuggest Edit
ACADIA Pharmaceuticals (formerly known as Receptor Technologies) is a biopharmaceutical company focused on the development and commercialization of medicines that address medical needs in central nervous system (CNS) disorders. Its main product is NUPLAZID that is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). The company also works on other solutions for dementia-related psychosis, Rett syndrome, negative symptoms of schizophrenia, etc.
| Type | Public | |
| Founded | 1993 | |
| HQ | San Diego, CA, US | Map |
| Website | acadia-pharm.com | |
| Employee Ratings | More | |
| Overall Culture | C- | More |
Recent NewsAll News
- ACAD SHAREHOLDER DEADLINE TOMORROW: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now
- ACAD 11-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Before the June 18th Deadline in Securities Fraud Lawsuit
- Should You Buy ACADIA Pharmaceuticals Stock At $22?
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
Key People/Management at ACADIA Pharmaceuticals
Stephen R. Davis
Chief Executive Officer, Director
Serge Stankovic
President
Austin D. Kim
Executive Vice President, General Counsel and Secretary
Daryl Dekarske
Senior Vice President, Global Head of Regulatory Affairs and Head of Translational Sciences
Stephanie Fagan
Senior Vice President Corporate Affairs and Chief Communications Officer
Kathie M. Bishop
Senior Vice President, Head of Rare Disease and External Innovation
ACADIA Pharmaceuticals Office Locations
ACADIA Pharmaceuticals has offices in San Diego and Princeton
San Diego, CA, US (HQ)
12830 El Camino Real #400
Princeton, NJ, US
502 Carnegie Center #300
San Diego, CA, US
3611 Valley Centre Dr Suite 300
ACADIA Pharmaceuticals Financials and Metrics
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals's revenue was reported to be $441.76 m in FY, 2020 which is a 30.3% increase from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2021) | 106.6m |
Gross profit (Q1, 2021) | 101.9m |
Gross profit margin (Q1, 2021), % | 95.6% |
Net income (Q1, 2021) | (66.4m) |
EBIT (Q1, 2021) | (66.8m) |
Market capitalization (12-Nov-2021) | 3.3b |
Closing stock price (12-Nov-2021) | 20.7 |
Cash (31-Mar-2021) | 304.5m |
EV | 3.1b |
ACADIA Pharmaceuticals's current market capitalization is $3.3 b.
Annual
Annual
Annual
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|
Net Income | (85.3m) | (140.2m) | (182.2m) | (88.0m) | (130.2m) | (214.8m) | (66.4m) |
Depreciation and Amortization | 785.0k | 1.5m | 2.1m | 664.0k | 1.4m | 2.1m | 895.0k |
Inventories | (557.0k) | 273.0k | (426.0k) | (37.0k) | (20.0k) | (1.7m) | (492.0k) |
Accounts Payable | 108.0k | 1.5m | 277.0k | (599.0k) | (756.0k) | (3.8m) | 356.0k |
| USD | FY, 2018 |
|---|---|
Revenue/Employee | 531.3k |
Financial Leverage | 1.1 x |
P/E Ratio | (8.3) |
ACADIA Pharmaceuticals Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| CerSci Therapeutics | August 24, 2020 | $52.5 m |
| ACADIA Pharmaceuticals A/S | ||
| ACADIA Pharmaceuticals GmbH | ||
| ACADIA Pharma Limited | ||
| CerSci Therapeutics Incorporated |
ACADIA Pharmaceuticals Cybersecurity Score
ACADIA Pharmaceuticals Environment, Social & Governance (ESG) Ratings
ACADIA Pharmaceuticals Online and Social Media Presence
ACADIA Pharmaceuticals's Trends
ACADIA Pharmaceuticals Company Culture
Overall Culture
C-
68/100
CEO Rating
B
77/100
Compensation
C+
73/100
ACADIA Pharmaceuticals News and Updates
June 17, 2021
ACAD SHAREHOLDER DEADLINE TOMORROW: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now
SAN FRANCISCO, June 17, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.
June 07, 2021
ACAD 11-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Before the June 18th Deadline in Securities Fraud Lawsuit
SAN FRANCISCO, June 07, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.
June 02, 2021
Should You Buy ACADIA Pharmaceuticals Stock At $22?
We believe that the stock price of ACADIA Pharmaceuticals, a biopharmaceutical company focused on neuroscience drugs, looks undervalued at current levels of around $22. ACAD stock is actually down 37% from levels of around $35 it was at on March 23, 2020, when broader markets made a bottom...
June 01, 2021
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the...
May 28, 2021
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit
SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.
May 25, 2021
Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before June 18, 2021; click here to submit trade information
ACADIA Pharmaceuticals Blogs
December 01, 2021
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
Content Import
Wed, 12/01/2021 - 09:03
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of S…
November 16, 2021
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
- Yours, Truly Debuts During National Family Caregivers Awareness Month to Encourage the Parkinson’s Disease Community to Preserve and Share Stories and Memories of Their Loved Ones SAN DIEGO --(BUSINESS WIRE)--Nov. 16, 2021-- Acadia Pharmaceuticals Inc.
November 08, 2021
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
- 3Q21 net sales of $131.6 million , a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third
November 02, 2021
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
- Analyses indicate ongoing need for approved treatments with favorable benefit-risk profile for treating patients with dementia-related hallucinations and delusions SAN DIEGO --(BUSINESS WIRE)--Nov. 2, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations
November 01, 2021
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
Content Import
Mon, 11/01/2021 - 16:07
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
…
October 27, 2021
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
Content Import
Wed, 10/27/2021 - 09:01
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
10/27/21
This release is a backfill f…
ACADIA Pharmaceuticals Frequently Asked Questions
When was ACADIA Pharmaceuticals founded?
ACADIA Pharmaceuticals was founded in 1993.
Who are ACADIA Pharmaceuticals key executives?
ACADIA Pharmaceuticals's key executives are Stephen R. Davis, Serge Stankovic and Austin D. Kim.
How many employees does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 601 employees.
What is ACADIA Pharmaceuticals revenue?
Latest ACADIA Pharmaceuticals annual revenue is $441.8 m.
What is ACADIA Pharmaceuticals revenue per employee?
Latest ACADIA Pharmaceuticals revenue per employee is $735 k.
Who are ACADIA Pharmaceuticals competitors?
Competitors of ACADIA Pharmaceuticals include Omeros, Supernus Pharmaceuticals and Alector.
Where is ACADIA Pharmaceuticals headquarters?
ACADIA Pharmaceuticals headquarters is located at 12830 El Camino Real #400, San Diego.
Where are ACADIA Pharmaceuticals offices?
ACADIA Pharmaceuticals has offices in San Diego and Princeton.
How many offices does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies